Laronib 100 mg (Larotrectinib) Capsules

Laronib 100 contains larotrectinib, a selective tropomyosin receptor kinase (TRK) inhibitor used as a targeted treatment for certain solid tumors with an NTRK gene fusion. It is intended for patients whose tumors demonstrate an NTRK fusion and who meet the relevant clinical criteria for targeted therapy.

Key Uses

• Used in the treatment of NTRK fusion-positive solid tumors.
• May be prescribed for adult and pediatric patients when the tumor contains an NTRK gene fusion without a known acquired resistance mutation.
• Used when the cancer has spread to other parts of the body (metastatic disease).
• May be considered when surgical removal of the tumor would be expected to cause significant morbidity.
• May be used when there is no satisfactory alternative treatment available.
• May be prescribed when the tumor has progressed following previous treatment.
• Treatment selection should be based on appropriate molecular or genetic testing confirming the presence of an NTRK gene fusion.

Therapeutic Effects

Larotrectinib works by inhibiting abnormal signaling caused by TRK proteins produced from NTRK gene fusions. In tumors driven by these gene fusions, continuous TRK signaling can contribute to cancer-cell growth and survival. By blocking this signaling pathway, larotrectinib can interfere with the molecular signals that support tumor-cell proliferation.

The therapeutic response can vary according to tumor type, genetic characteristics, disease stage, previous treatments, and individual patient factors. Therefore, larotrectinib should be used only after appropriate clinical assessment and confirmation of the relevant molecular alteration.

Active Ingredient

Larotrectinib — 100 mg

Each Laronib 100 capsule contains 100 mg of larotrectinib, provided as larotrectinib sulfate equivalent to 100 mg of larotrectinib. The corresponding amount of larotrectinib sulfate is approximately 123 mg per 100 mg capsule.

Pharmaceutical Form

• Generic Name: Larotrectinib
• Strength: 100 mg
• Dosage Form: Hard gelatin capsule
• Route of Administration: Oral
• Active Substance: Larotrectinib sulfate
• Therapeutic Category: Targeted anticancer therapy / TRK kinase inhibitor

Capsule Components

The reference formulation uses a hard gelatin capsule containing gelatin and titanium dioxide, with edible ink used for capsule printing. However, inactive ingredients and capsule specifications can vary between manufacturers and markets, so the physical product packaging and local prescribing information should be checked for the exact formulation being supplied.